EN DE
Watch Peptron Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Peptron Inc (087010) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Peptron Inc stock KRW 47,496, price KRW 93,400, that is 49.1% below the price, quality 38 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7087010005

PI Peptron Inc logo Thin data Nov 10, 2026

Peptron Inc

087010 · KQ
Very expensive, weak quality

Our calculation puts a fair price 49% below what the stock costs today.

Low debt
Revenue last quarter +48% vs. a year ago.
Expensive Growth (revenue 5y +12.5 %/yr in KRW)
Fair value 47,496 KRW · Strongly overvalued
Quality 38/100
Negative free cash flow
Trails peers (1/6)
Narrow moat 36/100
Thin data
Estimate
Watch Peptron Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

386,000 KRW 7,150 KRW Fair Value 47,496 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 7,150 KRW – 386,000 KRW · fair‑value band 35,622 KRW – 59,370 KRW · the 93,400 KRW price screens above the 47,496 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Peptron in your weekly email

Every Wednesday you see whether Peptron is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug.

Show moreShow less

Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease.

Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

Stock analysis

Peptron Inc (087010) currently trades at 93,400 KRW, while our estimate is 47,496 KRW, 49% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 35,622 KRW (bear) to 59,370 KRW (bull), the price of 93,400 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Peptron Inc reported revenue of 5.6B KRW in FY2025 versus 6.6B KRW in FY2021, a compound −4.0%/yr. Reported net income was −13.8B KRW in FY2025.

Key figures

Market cap 2.2T KRW (≈ $1.6B) Small · Return on equity −2,363% · Return on assets (EBIT) −18.9% (5-year average) · Operating margin −245% · Revenue (TTM) 5.8B KRW · Revenue growth (YoY) +47.8% · Free cash flow −23.6B KRW · Net debt 24.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (medium confidence).

What moves the price

The share trades about 76% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −18% fair-value upside, at −49%, 087010 screens richer than that median.

Fair Value

Bear 35,622 KRW Fair Value 47,496 KRW Bull 59,370 KRW
Price 93,400 KRW · Downside -49.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 22
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 60
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+78.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−569.7% (2020) → −377.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

087010 screens overvalued: fair value 49% below the price. Compare with MEDIPOST Co →

Compare Peptron Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2771 stocks

Beats the sector median on 1/6 measures
Overall it trails its sector peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −49.1% · Bottom 25%
Profitability
Return on assets −7.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 47.8% · Top 25%
Balance sheet
Debt / equity 0.18× · Above median

Valuation Multiplesvs Health Care median · lower = cheaper

P/B 15.29× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 10
FUTURE (revenue growth)100 · sector 30
PAST (return on equity)0 · sector 5
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Purple Biotech Ltd KTOV 0.0100 ILS 0.0160 ILS +60% vs 087010
Cell Biotech Co 049960 13,490 KRW 15,078 KRW +12% vs 087010
Panagene Inc 046210 1,056 KRW 1,152 KRW +9% vs 087010
MEDIPOST Co 078160 8,490 KRW 7,855 KRW −7% vs 087010
Biotoxtech Co 086040 2,345 KRW 1,916 KRW −18% vs 087010
Pluri Inc PSTI 3.51 ILS 2.83 ILS −19% vs 087010
Johnson & Johnson, JNJ $280.78 $168.85 −40% vs 087010
Eli Lilly and Company LLY $1,432 $749.92 −48% vs 087010
Bioneer Corporation 064550 6,860 KRW 3,547 KRW −48% vs 087010
Macrogen, Inc 038290 11,200 KRW 4,457 KRW −60% vs 087010

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Peptron Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Peptron Inc Fair Value". https://www.fairvalue-calculator.com/stock/087010

Frequently asked questions

Is Peptron Inc (087010) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 47,496 KRW versus a price of 93,400 KRW, about 49% lower (overvalued).
What is the fair value of 087010?
Our estimate for Peptron Inc is 47,496 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 93,400 KRW.
What is the quality score of 087010?
Peptron Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Peptron Inc (087010)?
Our calculated price target is the estimate of 47,496 KRW (as of Nov 10, 2026). Cautious scenario 35,622 KRW, optimistic scenario 59,370 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Peptron Inc stock forecast for 2026?
Our estimate puts fair value at 47,496 KRW, about 49% lower versus a price of 93,400 KRW (overvalued). Cautious scenario 35,622 KRW, optimistic scenario 59,370 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Peptron Inc (087010)?
Peptron Inc reported trailing-twelve-month revenue of about 5.8B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Peptron Inc (087010)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Peptron Inc it is 47,496 KRW per share (as of Nov 10, 2026), against a price of 93,400 KRW.
Is Peptron Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 087010 trades above its calculated fair value: price 93,400 KRW, fair value 47,496 KRW, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 087010?
No. The price is what the market pays today (93,400 KRW); the fair value is what the company's own numbers justify (47,496 KRW). For Peptron Inc the two are 45,904 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Peptron Inc worth?
The market values Peptron Inc at about 2.2T KRW (market capitalisation, as of Nov 10, 2026). Per share that is 93,400 KRW; our models calculate a fair value of 47,496 KRW per share.
What do the bullish and bearish scenarios say about 087010?
Our models span a range for Peptron Inc: cautious scenario 35,622 KRW, base 47,496 KRW, optimistic 59,370 KRW per share (as of Nov 10, 2026, price 93,400 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Peptron Inc (087010)?
Balance-sheet figures for Peptron Inc (as of Nov 10, 2026): debt of 0.18 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 087010 from its 52-week high?
Peptron Inc trades at 93,400 KRW, about 76% below its 52-week high of 386,000 KRW and 13% above the low of 82,900 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 47,496 KRW is for.
Which stocks are comparable to Peptron Inc?
From the same area (Healthcare) we also value MEDIPOST Co, Bioneer Corporation, Macrogen, Inc, Cell Biotech Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Peptron Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 93,400 KRW, calculated fair value 47,496 KRW (−49%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Peptron Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Peptron Inc (087010)?
The closing price on Nov 10, 2026 was 93,400 KRW. Our estimate is 47,496 KRW, about 49% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Peptron Inc right now?
The price sits above even our optimistic bull case (59,370 KRW). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Peptron Inc

How large is the market capitalisation of Peptron Inc (087010)?
The market capitalisation of Peptron Inc is 2.2T KRW (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of Peptron Inc (087010)?
The return on equity (ROE) of Peptron Inc is −2,363% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Peptron Inc (087010)?
On an EBIT basis the return on assets of Peptron Inc is −18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Peptron Inc (087010)?
The operating margin of Peptron Inc is −245% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Peptron Inc (087010)?
Revenue at Peptron Inc is growing +47.8% versus a year earlier (3y avg −1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Peptron Inc (087010) generate?
The free cash flow of Peptron Inc is −23.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Peptron Inc (087010) carry?
The net debt of Peptron Inc is 24.7B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Peptron Inc in the live analysis

One click puts Peptron Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.